Trial
NCT03694834
Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial Cancer
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
Merck Sharp & Dohme LLC
Condition
Endometrial Cancer
Intervention
Pembrolizumab
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-28